<DOC>
	<DOCNO>NCT00333190</DOCNO>
	<brief_summary>The purpose trial determine selectively remove small subset T cell , call CD8+ T cell , safe reduce risk graft versus host disease ( GVHD ) without lose anti-cancer effect .</brief_summary>
	<brief_title>CD8+ T Cell Depletion GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>- The patient admit hospital good donor find chemotherapy stem cell transplant . The patient remain hospital 8 day receive two chemotherapy drug ( fludarabine Busulfex ) intravenously day 4 day . - On third day patient finish chemotherapy , donor cell arrive Dana-Farber Cancer Institute lab remove CD8 cell . Then product give patient central line . If enough stem cell donor product , CD8 cell take , patient get whole product . - Just transplant , patient also take tacrolimus methotrexate help prevent GVHD . Tacrolimus pill take orally two time day . Methotrexate chemotherapy drug give intravenously day 1 , 3 6 transplant . In addition drug , participant also take antibiotic prevent infection Filgrastim ( G-CSF , neupogen ) white blood cell count well . - After stem cell infusion , check-ups blood test perform least week 1 month . At one month , bone marrow biopsy look donor 's cell participant bone marrow perform . After 1-month evaluation , patient see least every 2 week another bone marrow biopsy 3-4 month transplant . - After patient past 100 day since transplant , follow clinic blood work do least month 6 month post transplant . - The trial end 6 month transplant , patient track rest life look long-term effect transplant .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Hematologic malignancy candidate allogeneic nonmyeloablative stem cell transplantation AML ALL first subsequent remission , resistant untreated relapse marrow blast &lt; 20 % cellularity CML first subsequent chronic phase , accelerate phase Myelodysplastic syndrome &lt; 20 % marrow blast NHL Hodgkin 's lymphoma second great remission , partial remission salvage therapy , patient marrow involvement , &lt; 20 % involvement BM CLL RAI stage 24 , progress initial fludarabine contain therapy , BM involvement &lt; 20 % Multiple myeloma stage IIIII , first subsequent plateau phase &lt; 20 % BM plasma cell Available unrelated donor fully HLA match HLAA , B , C DRB1 Age 18 great Performance status 02 Life expectancy &gt; 100 day No HLAmatched relate donor available Myeloproliferative disorder CML MDS myeloproliferative feature , CMML High grade Burkitts Burkittslike NonHodgkin 's lymphoma Prior allogeneic stem cell transplant Active CNS involvement disease Uncontrolled infection Pregnancy Evidence HIV infection Heart failure uncontrolled medication Total bilirubin &gt; 2.0 mg/dl due hepatocellular dysfunction AST &gt; 2 x institutional upper limit normal Serum creatinine &gt; 2.0 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stem cell transplant</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>CD+8 T cell depletion</keyword>
</DOC>